"Pharmacogenetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
| Descriptor ID |
D010597
|
| MeSH Number(s) |
H01.158.273.343.750 H01.158.703.052 H02.628.479
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenetics".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenetics".
This graph shows the total number of publications written about "Pharmacogenetics" by people in this website by year, and whether "Pharmacogenetics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 4 | 4 | 8 |
| 2006 | 6 | 6 | 12 |
| 2007 | 7 | 1 | 8 |
| 2008 | 7 | 6 | 13 |
| 2009 | 4 | 5 | 9 |
| 2010 | 10 | 8 | 18 |
| 2011 | 6 | 5 | 11 |
| 2012 | 12 | 10 | 22 |
| 2013 | 9 | 11 | 20 |
| 2014 | 7 | 5 | 12 |
| 2015 | 7 | 4 | 11 |
| 2016 | 9 | 7 | 16 |
| 2017 | 5 | 4 | 9 |
| 2018 | 7 | 3 | 10 |
| 2019 | 9 | 4 | 13 |
| 2020 | 3 | 4 | 7 |
| 2021 | 3 | 6 | 9 |
| 2022 | 3 | 4 | 7 |
| 2023 | 1 | 2 | 3 |
| 2024 | 4 | 1 | 5 |
| 2025 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenetics" by people in Profiles.
-
Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clin Pharmacol Ther. 2026 Jan; 119(1):109-119.
-
Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges. Clin Pharmacol Ther. 2025 Oct; 118(4):778-789.
-
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia. JAMA Netw Open. 2025 06 02; 8(6):e2516296.
-
Pharmacogenomics of chemotherapy induced peripheral neuropathy using an electronic health record-derived definition: a genome-wide association study. Support Care Cancer. 2025 Apr 08; 33(5):362.
-
Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing. Clin Transl Sci. 2025 Apr; 18(4):e70193.
-
A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic Information. Clin Pharmacol Ther. 2025 Jun; 117(6):1793-1802.
-
Effects of Social Determinants and Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions. Ann Fam Med. 2024 Nov 01; 21(Suppl 3).
-
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3478-3490.
-
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun. 2024 May 01; 15(1):3681.
-
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6.